Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank

Holly Pavey; Spoorthy Kulkarni; Angela Wood; Yoav Ben-Shlomo; Peter Sever; Carmel McEniery; Ian Wilkinson

doi:10.1371/journal.pone.0276781

Loading metrics

Open Access

Peer-reviewed

Research Article

Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank

Holly Pavey ,

Roles Data curation, Formal analysis, Methodology, Writing – original draft

* E-mail: hp409@medschl.cam.ac.uk

Affiliation Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom

https://orcid.org/0000-0001-5014-5118

⨯
Spoorthy Kulkarni,

Roles Writing – review & editing

Affiliation Department of Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

https://orcid.org/0000-0003-2827-214X

⨯
Angela Wood,

Roles Formal analysis, Methodology, Supervision, Writing – review & editing

Affiliations British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, United Kingdom, Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, United Kingdom, National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom, The Alan Turing Institute, London, United Kingdom
⨯
Yoav Ben-Shlomo,

Roles Formal analysis, Methodology, Writing – review & editing

Affiliation Population Health Sciences, University of Bristol, Bristol, United Kingdom
⨯
Peter Sever,

Roles Writing – review & editing

Affiliation National Heart and Lung Institute, Imperial College London, London, United Kingdom
⨯
Carmel McEniery,

Roles Supervision, Writing – original draft, Writing – review & editing

Affiliation Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom
⨯
Ian Wilkinson

Roles Supervision, Writing – original draft, Writing – review & editing

Affiliation Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom
⨯

Primary hypertension, anti-hypertensive medications and the risk of severe COVID-19 in UK Biobank

Holly Pavey,
Spoorthy Kulkarni,
Angela Wood,
Yoav Ben-Shlomo,
Peter Sever,
Carmel McEniery,
Ian Wilkinson

Published: November 9, 2022
https://doi.org/10.1371/journal.pone.0276781

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

COVID 19
Is the Subject Area "COVID 19" applicable to this article?

Thanks for your feedback.
Cardiovascular disease risk
Is the Subject Area "Cardiovascular disease risk" applicable to this article?

Thanks for your feedback.
Antihypertensives
Is the Subject Area "Antihypertensives" applicable to this article?

Thanks for your feedback.
Antihypertensive drug therapy
Is the Subject Area "Antihypertensive drug therapy" applicable to this article?

Thanks for your feedback.
Hypertension
Is the Subject Area "Hypertension" applicable to this article?

Thanks for your feedback.
Virus testing
Is the Subject Area "Virus testing" applicable to this article?

Thanks for your feedback.
Primary hypertension
Is the Subject Area "Primary hypertension" applicable to this article?

Thanks for your feedback.
Pulmonary hypertension
Is the Subject Area "Pulmonary hypertension" applicable to this article?

Thanks for your feedback.